

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

B&K CORPORATION LIMITED
華芒生物科技（青島）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2396)

VOLUNTARY ANNOUNCEMENT

**FULL PATIENT ENROLLMENT IN THE PHASE II
CLINICAL TRIAL OF PRO-101-2 FOR THE TREATMENT OF
DIABETIC FOOT ULCERS**

This announcement is made by B&K Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) and potential investors of the Company about the latest business updates of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Phase II clinical trial (the “**Clinical Trial**”) of Pro-101-2, a product developed by the Company for the treatment of diabetic foot ulcers, has recently completed full patient enrollment. Pro-101-2 is one of the Company’s core products. This Clinical Trial is a randomized, double-blind, placebo-controlled study designed to further evaluate the efficacy and safety of recombinant human platelet-derived growth factor (rhPDGF-BB) gel in the treatment of diabetic foot ulcers, and to generate key parameters for the design of the subsequent Phase III clinical trial based on a large cohort of enrolled subjects. The completion of patient enrollment in the Phase II clinical trial of Pro-101-2 represents another significant research and development progress for the Company in the field of diabetic foot ulcer treatment.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: THE COMPANY CANNOT GUARANTEE THAT THE COMPANY WILL BE ABLE TO ULTIMATELY SUCCESSFULLY DEVELOP AND MARKET PRO-101-2. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
B&K Corporation Limited
Ms. JIA Lijia

Executive Director and Chairperson of the Board

Qingdao, the PRC
13 July 2026

As of the date of this announcement, the Board comprises (i) Ms. JIA Lijia, Mr. WANG Kelong, Dr. ZHAI Junhui and Mr. MIAO Tianxiang as executive Directors; (ii) Ms. LIN Ying and Mr. YUAN Fei as non-executive Directors; and (iii) Mr. FOK Chi Tat Michael, Mr. LI Jiayan and Mr. YUE Yichun as independent non-executive Directors.